Thus, IL-12 and IFN-γ release from the cryogel that is adjacent to the tumor enables TAM reprogramming and reversal of the immunosuppressive TME while avoiding dose-limiting toxicities of systemically administered pro-inflammatory cytokines. This evidence concerns the gene IFNG and neoplasm.